Advanced

Prospective study of genital human papillomaviruses and nonmelanoma skin cancer.

Andersson, Kristin LU ; Luostarinen, Tapio; Söderlund Strand, Anna LU ; Langseth, Hilde; Gislefoss, Randi E; Forslund, Ola LU ; Pawlita, Michael; Waterboer, Tim and Dillner, Joakim LU (2013) In International Journal of Cancer 133(8). p.1840-1845
Abstract
Genital high-risk human papillomaviruses (HPVs) cause cervical cancer and are also found in a small proportion of nonmelanoma skin cancers (NMSCs). We used cancer registry linkages to follow the 856,000 serum donors included in the Southern Sweden Microbiology Biobank or the Janus Biobank in Norway, for incident skin cancers occurring up to 30 years after serum donation. Serum samples taken before diagnosis of squamous cell carcinoma (SCC) (N = 633), basal cell carcinoma (BCC) (N = 1990) or other NMSC (N = 153) and matched samples from control donors were tested for antibodies to the genital HPV types 16 and 18. Both HPV 16 and 18 were associated with increased risk for SCC [odds ratio (OR) 1.6, 95% confidence interval (CI) 1.1-2.6 and OR... (More)
Genital high-risk human papillomaviruses (HPVs) cause cervical cancer and are also found in a small proportion of nonmelanoma skin cancers (NMSCs). We used cancer registry linkages to follow the 856,000 serum donors included in the Southern Sweden Microbiology Biobank or the Janus Biobank in Norway, for incident skin cancers occurring up to 30 years after serum donation. Serum samples taken before diagnosis of squamous cell carcinoma (SCC) (N = 633), basal cell carcinoma (BCC) (N = 1990) or other NMSC (N = 153) and matched samples from control donors were tested for antibodies to the genital HPV types 16 and 18. Both HPV 16 and 18 were associated with increased risk for SCC [odds ratio (OR) 1.6, 95% confidence interval (CI) 1.1-2.6 and OR 1.7, 95% CI 1.1-2.5, respectively] and other NMSC (OR 2.3, 95% CI 1.0-5.2 and OR 3.5, 95% CI 1.4-8.7, respectively), but not for BCC. Tumor blocks from HPV16 or 18 seropositive cases were tested with real-time polymerase chain reaction for presence of HPV16 or 18 DNA. No HPV18 DNA was found and only four of 79 SCC cases (two of which were from the perineum/perianal area), one of 221 BCC cases and zero of five cases with other NMSC contained HPV16 DNA. In conclusion, we found prospective evidence that HPV16 and 18 antibodies associate with SCC and other NMSC risk, but not with BCC risk. As only a small proportion of seropositive subjects had evidence of the corresponding HPV DNA in the tumor, most of this excess risk is likely to be due to confounders associated with genital HPV infection. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
International Journal of Cancer
volume
133
issue
8
pages
1840 - 1845
publisher
John Wiley & Sons
external identifiers
  • wos:000322908600009
  • pmid:23553409
  • scopus:84881542019
ISSN
0020-7136
DOI
10.1002/ijc.28188
language
English
LU publication?
yes
id
4cbd3b8b-0111-4f20-ba30-50078ffa1d02 (old id 3734220)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/23553409?dopt=Abstract
date added to LUP
2013-05-02 10:34:19
date last changed
2018-10-03 10:09:32
@article{4cbd3b8b-0111-4f20-ba30-50078ffa1d02,
  abstract     = {Genital high-risk human papillomaviruses (HPVs) cause cervical cancer and are also found in a small proportion of nonmelanoma skin cancers (NMSCs). We used cancer registry linkages to follow the 856,000 serum donors included in the Southern Sweden Microbiology Biobank or the Janus Biobank in Norway, for incident skin cancers occurring up to 30 years after serum donation. Serum samples taken before diagnosis of squamous cell carcinoma (SCC) (N = 633), basal cell carcinoma (BCC) (N = 1990) or other NMSC (N = 153) and matched samples from control donors were tested for antibodies to the genital HPV types 16 and 18. Both HPV 16 and 18 were associated with increased risk for SCC [odds ratio (OR) 1.6, 95% confidence interval (CI) 1.1-2.6 and OR 1.7, 95% CI 1.1-2.5, respectively] and other NMSC (OR 2.3, 95% CI 1.0-5.2 and OR 3.5, 95% CI 1.4-8.7, respectively), but not for BCC. Tumor blocks from HPV16 or 18 seropositive cases were tested with real-time polymerase chain reaction for presence of HPV16 or 18 DNA. No HPV18 DNA was found and only four of 79 SCC cases (two of which were from the perineum/perianal area), one of 221 BCC cases and zero of five cases with other NMSC contained HPV16 DNA. In conclusion, we found prospective evidence that HPV16 and 18 antibodies associate with SCC and other NMSC risk, but not with BCC risk. As only a small proportion of seropositive subjects had evidence of the corresponding HPV DNA in the tumor, most of this excess risk is likely to be due to confounders associated with genital HPV infection.},
  author       = {Andersson, Kristin and Luostarinen, Tapio and Söderlund Strand, Anna and Langseth, Hilde and Gislefoss, Randi E and Forslund, Ola and Pawlita, Michael and Waterboer, Tim and Dillner, Joakim},
  issn         = {0020-7136},
  language     = {eng},
  number       = {8},
  pages        = {1840--1845},
  publisher    = {John Wiley & Sons},
  series       = {International Journal of Cancer},
  title        = {Prospective study of genital human papillomaviruses and nonmelanoma skin cancer.},
  url          = {http://dx.doi.org/10.1002/ijc.28188},
  volume       = {133},
  year         = {2013},
}